US Health and Human Services Secretary Alex Azar said Operation Warp Speed has applied “the same methods” to therapeutics as it has to support vaccines and there could be "tens or hundreds of thousands of doses" of Regeneron's antibody cocktail available soon.
“We've applied the same methods to supporting therapeutics too,” he said during a Goldman Sachs Healthcare virtual event on Thursday. “That includes, for instance, support for both development and manufacturing of Regeneron’s antibody cocktail, of which we could have tens or hundreds of thousands of doses this fall, pending FDA authorization.”
“OWS supported clinical trials continue for remdesivir in combination with other drugs. In addition to anticoagulants and other options,” Azar said.
“We're also supporting several randomized controlled clinical trials to produce more data on convalescent plasma,” he added, noting “to which Americans have enjoyed broader access than anywhere else on Earth.”
Some background: Regeneron's experimental antibody treatment is still in large-scale clinical trials, but has been available for compassionate use, something the FDA has to approve on an individual basis, like it did for President Trump.
The antibody therapy is a combination of two monoclonal antibodies that is designed specifically to block infectivity of SARS-CoV-2, the virus that causes Covid-19, according to the company's statement.
A cocktail antibody therapy uses two or more lab-engineered antibodies. Regeneron's cocktail includes a monoclonal antibody that targets the spike protein the virus uses to drill into healthy cells, and another antibody that targets a different part of the novel coronavirus. With two, the hope is to trap and shut down viral replication.